Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
344 patients ≥65 years were included (acalabrutinib = 2,662; zanubrutinib = 1,577; ibrutinib = 1,105).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Average outpatient visits PPPY were lowest for zanubrutinib (zanubrutinib: 9.7, acalabrutinib: 10.9, ibrutinib: 11.5; = .0018). [CONCLUSIONS] This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.
[BACKGROUND] Chronic lymphocytic leukemia (CLL) commonly affects older patients, who often endure greater health disparities and treatment burdens.
APA
Ailawadhi S, Challagulla S, et al. (2026). Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia.. Expert review of hematology, 1-8. https://doi.org/10.1080/17474086.2026.2628534
MLA
Ailawadhi S, et al.. "Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia.." Expert review of hematology, 2026, pp. 1-8.
PMID
41666415
Abstract
[BACKGROUND] Chronic lymphocytic leukemia (CLL) commonly affects older patients, who often endure greater health disparities and treatment burdens. This study assessed treatment utilization patterns, discontinuation, and healthcare resource utilization (HCRU) of first-line (1L) use of Bruton tyrosine kinase inhibitors (BTKis) in elderly patients with CLL.
[RESEARCH DESIGN AND METHODS] A retrospective observational study using the Symphony Integrated Dataverse identified CLL patients aged ≥65 years initiating a 1L BTKi (zanubrutinib, acalabrutinib, ibrutinib; 01/2022-11/2024). Baseline characteristics and outcomes were reported for each BTKi. Treatment discontinuation rate was estimated at 3, 4, 5, 6, 12, 18, and 24 months, and by time to discontinuation (TTD), using Kaplan-Meier method. HCRU (outpatient, inpatient, and other services) was evaluated as per patient per year (PPPY).
[RESULTS] A total of 5,344 patients ≥65 years were included (acalabrutinib = 2,662; zanubrutinib = 1,577; ibrutinib = 1,105). Baseline characteristics were similar across each BTKi. Zanubrutinib had the longest median TTD overall (zanubrutinib: 22.8 months, acalabrutinib: 17.4 months, ibrutinib: 14.3 months; < .0001). Average outpatient visits PPPY were lowest for zanubrutinib (zanubrutinib: 9.7, acalabrutinib: 10.9, ibrutinib: 11.5; = .0018).
[CONCLUSIONS] This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.
[RESEARCH DESIGN AND METHODS] A retrospective observational study using the Symphony Integrated Dataverse identified CLL patients aged ≥65 years initiating a 1L BTKi (zanubrutinib, acalabrutinib, ibrutinib; 01/2022-11/2024). Baseline characteristics and outcomes were reported for each BTKi. Treatment discontinuation rate was estimated at 3, 4, 5, 6, 12, 18, and 24 months, and by time to discontinuation (TTD), using Kaplan-Meier method. HCRU (outpatient, inpatient, and other services) was evaluated as per patient per year (PPPY).
[RESULTS] A total of 5,344 patients ≥65 years were included (acalabrutinib = 2,662; zanubrutinib = 1,577; ibrutinib = 1,105). Baseline characteristics were similar across each BTKi. Zanubrutinib had the longest median TTD overall (zanubrutinib: 22.8 months, acalabrutinib: 17.4 months, ibrutinib: 14.3 months; < .0001). Average outpatient visits PPPY were lowest for zanubrutinib (zanubrutinib: 9.7, acalabrutinib: 10.9, ibrutinib: 11.5; = .0018).
[CONCLUSIONS] This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.
같은 제1저자의 인용 많은 논문 (2)
- Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
- Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US).